Enzon Pharmaceuticals (OTCMKTS:ENZN) Posts Earnings Results

Enzon Pharmaceuticals (OTCMKTS:ENZN) issued its earnings results on Friday. The biotechnology company reported ($0.01) EPS for the quarter, Zacks reports.

Enzon Pharmaceuticals Stock Performance

Shares of Enzon Pharmaceuticals stock opened at $0.09 on Friday. The stock has a market capitalization of $6.99 million, a PE ratio of 9.43 and a beta of 0.25. Enzon Pharmaceuticals has a 52 week low of $0.07 and a 52 week high of $0.24. The stock has a 50 day moving average price of $0.10 and a two-hundred day moving average price of $0.12.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.